Home    eJManager.com Add Your Journal   |    Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Research

Vet World. 2010; 3(10): 449-452


Safety of Moxifloxacin following repeated intramuscular administration in Wistar rats

K. A. Sadariya, A. K. Gothi, S. D. Patel, S. K. Bhavsar, A. M. Thaker.

Abstract
Moxifloxacin is a novel fourth generation fluoroquinolone with broad spectrum of antibacterial activity. The study was conducted to evaluate the safety of Moxifloxacin (5.0 mg/kg) after repeated intramuscular administration at 24 h interval for 14 days in male and female wistar rats. Hematological (Haemoglobin, RBC, WBC, MCV, MCH, MCHC, HCT and DLC), blood biochemical parameters (AST, ALT, ALP, Total Bilirubin, Total Serum Protein, Serum Albumin, Globulin, Serum Creatinine, Urea, Uric acid and Blood glucose) and histopathological examination of various tissues were carried out in the present study. Male and female animals of any group did not reveal any clinical symptoms and mortality attributable to the 14 days intramuscular administration of Moxifloxacin. The data were compared by unpaired two tail `t` test using Graph
Pad Prism (Version 4.00). All above hematological and blood biochemical parameters were found to fluctuate within normal range during treatment period and the mean values were not significantly differ (p < 0.05) from corresponding control values. Moreover, no gross or microscopic changes were found in the liver, kidney, heart, spleen, stomach, intestine and joint cartilages of the treated wistar rats. Results indicate that daily administration of Moxifloxacin for 14 days seems to be safe and well tolerated in rats.

Key words: Moxifloxacin, Wistar rats, Safety study, Fluoroquinolone, Antibiotic, Antibacterial



Share this Article





ScopeMed Home
Follow ScopeMed on Twitter
Article Tools
Job Opportunities/Service Offers
eJManager OJMS
eJPort Journal Hosting
About ScopeMed
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of eJManager LLC Publishing for Scientific Publications. Copyright © ScopeMedź International Medical Journal Management and Indexing System.
Scopemed Buttons